Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Trial to Investigate Safety, Tolerability and Exploratory Clinical Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (PACE-CPVT)

NCT07263139 is registered in ClinicalTrials.gov with Agiana Pharmaceuticals as lead sponsor.

NCT NCT07263139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07263139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Trial to Investigate Safety, Tolerability and Exploratory Clinical Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (PACE-CPVT)
Lead sponsor
Agiana Pharmaceuticals
Phase
Phase 2
Overall status
Recruiting
Start date
January 2, 2026
Completion date
June 30, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

catecholaminergic polymorphic ventricular tachycardia